Bioanalysis Zone

Announcing the Winner of the Bioanalysis Zone 2016 New Investigator Award


Bioanalysis Zone, the knowledge hub for the bioanalysis industry, has named Panagiotis A Vorkas, the winner of the 2016 New Investigator Award, a prestigious recognition of the most promising early-career researchers in the bioanalysis field.

The New Investigator Award is given annually by Bioanalysis Zone and Bioanalysis, a MEDLINE-indexed journal covering the latest scientific, technical and regulatory developments relevant to bioanalysts. Both the online community and the journal are produced by Future Science Group.

Award-winner Panagiotis was nominated by Prof Elaine Holmes, his supervisor at Imperial College London (UK) in honor for his work in developing a metabolic profiling workflow utilizing two untargeted UPLC–MS methods which, when combined, expanded metabolome coverage. The rigorous optimization of these methods and implementation of new and much needed concepts in quality control, suggestions in post-acquisition artefact exclusion, structural assignment of a wide range of metabolites and development of an experimental setup to achieve this resulted in several key publications.

Application of the developed pipeline in different manifestations of cardiovascular disease, demonstrated its superior ability to expand metabolite coverage and most importantly their efficiency – as untargeted methods – to detect previously unreported but biologically important molecules and elucidate dysregulated pathways in disease.

On receiving the award Panagiotis commented, “I am deeply honored to receive this year’s Bioanalysis Zone New Investigator Award. I see this award as a huge encouragement in my career to continue contributing to advancements in bioanalysis. I am confident that the award will enhance my career prospects and hope to enjoy the professional success of past recipients.”

A full presentation with Panagiotis is available at (

As the winner of the New Investigator Award, Panagiotis will present his work at the European Bioanalysis Forum (EBF) Open Symposium, Barcelona, Spain on 17 November 2016. He also receives a one-year subscription to Bioanalysis and US $1000 courtesy of award sponsors Waters Corporation (MA, USA), a provider of laboratory solutions and software in separations science, mass spectrometry and thermal analysis. He will also present his work in a Bioanalysis Zone webinar on 30th November 2016. Details and registration information found here:

“It’s been delightful running this year’s award. As ever, the NIA has gone from strength to strength each year attracting a number of hugely talented bioanalysts working on a variety of projects spanning a wide range of present day bioanalytical challenges” said Ayan Ali, Digital Editor for Bioanalysis Zone.

“I would like to congratulate Panagiotis Vorkas and to all this year’s nominees for their hard work and contribution to the bioanalytical field.”

Our 2015 winner, Xiwei (Emmi) Zheng commented, “Bioanalysis New Investigator Award is important in the way that provides outstanding-young scientists with an opportunity and a route to show their work to others worldwide in the field of bioanalysis from both academia and industry. Through this award, the newest and frontier research topics are also gathered and highlighted that can guide the development and improvement of novel techniques and methods in bioanalysis. I think this award is not only important to the winner, but also to the participants and the public in terms of knowledge sharing and spreading.”

Panagiotis was selected from seven finalists, named from an initial field of 25 young scientists nominated by their peers and mentors. The additional finalists were Andrew Baldwin (University of Oxford), Caroline Johnson (The Scripps Research Institute), Casey Burton (Missouri University of Science and Technology), Egan Doeven (Deakin University) and Phillip Trefz (Breath Research & Technology, University of Rostock). Full profiles of all finalists are available at

“I am extremely honored to have been invited to act as one of the judges for this prestigious award” commented Dr. Neil Spooner (Spooner Bioanalytical Solutions) “I am a great believer in encouraging the development of the new and exciting talent we need to face the bioanalytical challenges of the future and for them to bring forwards the novel approaches and ideas that will be the lifeblood of our discipline in the years to come.”

Dr. Erin Chambers is a Director in the Scientific Operations group at Waters Corporation. She recently served as a judge for the Bioanalysis Zone New Investigator Award.  “We are a company that, above all, values the quality of science. To be true to our reputation, we should be supporting others who share similar ideals. We have excellent scientists who work at Waters” said Dr. Chambers. “It’s our responsibility to support others and their research, whose work we care about and believe in. Waters plays an important role in advancing science. We primarily do this through technological innovation, but we also champion the scientists – new and experienced – who are moving scientific research forward.”

Nominations are currently being solicited for the 2017 award. See or contact the Editor Ayan Ali directly (

More details on the 9th EBF Open Symposium can be found at



About Bioanalysis Zone

Since launching in 2011, Bioanalysis Zone has attracted over 6,000 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, original research exclusive interviews and commentaries.

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio includes two imprints: Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.


Leave A Comment